Abstract. ACTH-independent macronodular adrenal hyperplasia (AIMAH) is a rare cause of Cushing's syndrome. Bilateral adrenalectomy is considered to be a standard therapy for AIMAH, although lifetime replacement of glucocorticoids is necessary after the procedure. This paper describes a subject with AIMAH who underwent unilateral adrenalectomy of the predominantly enlarged gland and subsequently displayed an improvement in insulin resistance and diabetes mellitus, the cardinal symptoms before the operation, concomitant with alleviation of abnormal cortisol secretion. The patient was a 61-year-old man with a body mass index of 25.6 kg/m 2 . He was diagnosed as having diabetes mellitus, hypertension, and hyperlipidemia at 50 years of age. Eight years after diagnosis, bilateral enlargement of the adrenal glands was revealed by chance upon computed tomography of the abdomen. Typical manifestations of Cushing's syndrome were not demonstrated. Basal levels of serum and urinary cortisol had not increased, although the serum cortisol level displayed no circadian rhythm and no response to the administration of dexamethasone. Despite sulfonylurea treatment, the patient's HbA 1C level was as high as 7.6% (normal range 4.3-5.8%). Fasting insulin concentration was increased to 42.6 mU/ml, and the homeostasis model insulin resistance index (HOMA-R) was calculated to be 15.5 (with a normal range of less than 2.5), indicating severe insulin resistance. Unilateral adrenalectomy of the predominantly enlarged gland revealed that the resected gland consisted of multiple nodules of various sizes. Based on endocrinological, radiological, and pathological findings, a diagnosis of AIMAH was made. Ten months after the unilateral adrenalectomy, cortisol circadian rhythms were restored, and serum cortisol concentration was suppressed in response to the administration of low doses of dexamethasone, suggesting an improvement in the cortisol secretory pattern. Levels of HbA 1C , fasting insulin, and HOMA-R decreased to 5.7%, 12.7mU/ml, and 2.2, respectively. An improvement in hyperlipidemia was also observed. Insulin resistance and glucose intolerance are recognized as features of mild hypercortisolism. In the present case, unilateral adrenalectomy was effective in ameliorating insulin resistance and improving glycemic control. Unilateral adrenalectomy might be an alternative therapy for improvement of glucose and lipid metabolism in subjects with AIMAH.
P450C11 [4] . Unilateral or subtotal adrenalectomy may be another choice of therapy [5, 6] . Lamas and colleagues recently reported 4 subjects with AIMAH followed up for 30-137 months after unilateral adrenalectomy [7] . In these 4 subjects, clinical manifestations of Cushing's syndrome were ameliorated, although abnormalities in cortisol secretion were not normalized. During the follow-up period, enlargement of the residual adrenal gland was not indicated.
Despite bilaterally enlarged glands, the degree of hypercortisolism is occasionally mild in subjects with AIMAH [8, 9] . Subjects with mild hypercortisolism, such as preclinical Cushing's syndrome or adrenal incidentalomas, often display insulin resistance and glucose intolerance as their cardinal symptoms [10] [11] [12] [13] . These features of the metabolic syndrome are considered to increase the risk of cardiovascular events. This paper reports on a patient with AIMAH and features of the metabolic syndrome for whom unilateral adrenalectomy of the predominantly enlarged gland was very effective in ameliorating insulin resistance and improving glycemic control and was associated with alleviation of abnormal cortisol secretion.
Case report
The patient was a 61-year-old man. He was diagnosed as having atrial fibrillation at the age of 45. His father had hypertension and cerebral infarction, and his mother had Graves' disease. At 50 years of age, he was diagnosed as having diabetes mellitus, hypertension, and hyperlipidemia, and medical treatment was started. At the age of 58, he was found to have abnormal test results for liver function, and fatty liver and bilateral enlargement of the adrenal glands was indicated by abdominal computed tomography. He was referred to the authors' division for further evaluation.
His height was 166 cm, weight 71 kg, and body mass index (BMI) 25.6 kg/m 2 . His blood pressure was 150/86 mmHg, while he was taking nifedipine 40 mg daily. His face was slightly plethoric, although a moon face and acne were not observed. Background diabetic retinopathy was indicated. Buffalo hump, abdominal striae, ecchymosis and easy bruisability, and pretibial edema were not found. The Achilles tendon reflex and sense of vibration in the legs were slightly diminished.
Routine laboratory examination indicated increased levels of transaminases (AST 74 mU/ml and ALT 111 mU/ml, respectively, with a normal range of less than 30 mU/ml After an intravenous bolus of human CRH 100 mg not suppressed with an overnight dexamethasonse suppression test. The levels of serum cortisol and urinary 17-hydroxycorticosteroid excretion did not display any response to low-dose and high-dose dexamethasone administration. Neither plasma ACTH nor serum cortisol concentrations increased with an intravenous bolus of human CRH 100 mg (Mitsubishi-Tokyo, Tokyo, Japan) ( Table 2) . Table 3 shows data regarding diabetes mellitus. Fasting insulin concentration was as high as 42.6 mU/ ml, and the homeostasis model insulin resistance index [HOMA-R = fasting insulin (mU/ml) × fasting glucose (mg/dl)/405] [14] was calculated to be 15.5, suggesting severe insulin resistance (with a normal value of less than 2.5) [15] . Although this data was collected with the patient taking glibenclamide the day before, HOMA-R is proven to reflect insulin sensitivity in diabetic subjects treated with sulfonylureas [16, 17] and to be a reliable indicator of insulin sensitivity during follow-up of diabetic patients [18] . Urinary C-peptide excretion also increased. Oral challenge of 75 g glucose revealed diabetic glucose tolerance, although an insulinogenic index, a marker of early phase insulin response [19] , was within the normal range.
Bilateral enlargement of the adrenal glands was found in abdominal computed tomography, and enlargement was especially prominent in the right gland (Fig. 1) . Bilateral uptake of 131 I-adosterol was observed in adrenal scintigraphy, and uptake in the right gland was also marked (Fig. 2) . Based on these examination results, the patient was diagnosed as having Cushing's syndrome due to bilateral hyperplasia of the adrenal glands, possibly due to AIMAH.
Regarding surgical treatment, the patient did not wish to undergo bilateral adrenalectomy because of the necessity of lifetime replacement of glucocorticoids. Therefore, unilateral adrenalectomy of the predominantly enlarged right adrenal gland was performed. The resected gland was 8.5 × 6.0 × 1.5 cm in size, and consisted of multiple nodules with sizes ranging from several mm to 15 mm in the greatest diameter (Fig. 3) . Histological examination revealed that the nodules comprised mostly adrenocortical clear-type cells with some areas of compact-type cells (Fig. 4) . A diagnosis of AIMAH was made. Although glucocorticoids were not substituted postoperatively, there were no manifestations of adrenal insufficiency. Postoperative laboratory data are summarized in Table 4 . The plasma ACTH level was normalized 10 months after the operation, and simultaneously, the peak value of plasma ACTH after CRH loading also gradually increased. Basal levels of serum cortisol remained unchanged, although the cortisol circadian rhythm and suppression by dexamethasone improved. Urinary cortisol excretion tended to decrease. Glycemic control improved remarkably despite a reduction in the daily dose of glibenclamide. A point of note is that fasting insulin, HOMA-R, and urinary C-peptide excretion decreased to the normal range 10 months after the operation. Two years later, levels of HbA 1C and serum triglyceride were kept at less than 6.0% and 100 mg/dl, respectively, by using lower doses of sulfonylurea and bezafibrate. The size of the residual left adrenal gland remained unchanged as shown by repeated computed tomography (Fig. 1) . BMI and blood pressure were also essentially unchanged throughout the observation period (data not shown), requiring anti-hypertensive medication. Levels of AST and ALT decreased to 30-50 mU/ml and 40-50 mU/ml, respectively.
Discussion
AIMAH, first reported in 1964 [20] , is a rare form of Cushing's syndrome, and the prevalence is estimated to be at around 1% of Cushing's syndrome [21] . The manifestations of hypercortisolism are occasionally mild despite bilaterally enlarged adrenal glands. The reason for this is attributed to inefficient cortisol synthesis due to immature enzymatic activity of the hyperplastic adrenal tissue [8, 9] . This paper has reported a patient having AIMAH with normal basal values of serum and urinary cortisol. He lacked typical physical manifestations of Cushing's syndrome but displayed insulin resistant diabetes mellitus, hypertension, and hypertriglyceridemia, all of which are manifestations of the metabolic syndrome. After unilateral adrenalectomy of the predominantly enlarged gland, insulin resistance, glycemic control, and hypertriglyceridemia improved markedly.
An excess of glucocorticoids is known to cause both insulin resistance and defective insulin secretion [22] . Insulin resistance and glucose intolerance are often observed in patients with mild hypercortisolism, such as preclinical Cushing's syndrome or adrenal incidentalomas [11] [12] [13] . Leibowitz et al. also demonstrated that pre-clinical Cushing's syndrome is frequently found in obese diabetic patients with poor glycemic control [10] . Furthermore, insulin resistance was in fact ameliorated after removal of such adrenal incidentalomas [23] . Collectively, subtle excess and/or abnormalities in the secretory pattern of glucocorticoids may account for insulin resistance and glucose intolerance. In the present case, basal levels of serum and urinary cortisol were within the normal ranges, although the abnormalities in cortisol secretory pattern were evident before the operation. Both endogenous cortisol's circadian rhythm and response to dexamethasone were defective. The plasma ACTH level was suppressed and did not respond to stimulation by CRH. Concomitantly, profound insulin resistance was observed, as indicated by the increased levels of fasting insulin, HOMA-R, and urinary C-peptide excretion. The early-phase insulin response after the glucose load, assessed by an insulinogenic index, had not deteriorated, in contrast to subjects with typical Type 2 diabetes [19, 24] . After the removal of the predominantly enlarged gland, most of the abnormalities in the cortisol secretory pattern improved, and urinary cortisol excretion decreased slightly. The mechanisms of these improvements are unclear, although the reduction in adrenal tissue mass may be important [7, 9] . In parallel with these improvements, the degree of insulin resistance and hyperglycemia improved markedly. Therefore, an abnormal secretory pattern of glucocorticoids is likely to play an important role in the etiology of insulin resistance and glucose intolerance of the present case. Unilateral adrenalectomy could be a choice of the therapy for reduction of manifestations of the metabolic syndrome in subjects with AIMAH. An aspect that should be emphasized is that this procedure also has the advantage of not requiring glucocorticoid replacement. At present, criteria for unilateral adrenalectomy in subjects with AIMAH are not well established. Predominant enlargement of the unilateral adrenal gland is occasionally observed in patients with AIMAH [25] . Unilateral adrenalectomy may be suitable, especially if the unilateral gland is predominantly enlarged, as in the present case. If there is no significant difference in the size of bilaterally enlarged glands, a subtotal rather than unilateral adrenalectomy may be more appropriate. However, since there are only a few case reports of subtotal adrenalectomy in patients with AIMAH [5, 6] , criteria for subtotal adrenalectomy also remain to be established.
It is evident that both adrenal glands have the same pathogenic abnormalities in subjects with AIMAH. Therefore, the residual adrenal gland may grow back and worsen the metabolic syndrome after a period of time. In the present case, the residual left gland did not display any enlargement for at least 2 years after the operation. Similarly, enlargement of the residual gland was not observed during 62-125 months in 4 patients with AIMAH who underwent unilateral adrenalectomy [7] . A portion of AIMAH is known to have specific membrane receptors for gastric inhibitory polypeptide, catecholamines, vasopression, etc., and these hormones are supposed to play a pivotal role in the pathogenesis of AIMAH [2] . Propranolol was also reported to be effective in limiting enlargement of the residual gland in a man with b-adrenergic receptormediated AIMAH who underwent unilateral adrenalectomy [26] . As far as is known, there is no case report yet in which the residual adrenal gland displays significant enlargement after unilateral adrenalectomy for AIMAH. However, careful attention must be paid after the procedure.
In conclusion, this paper has reported on a subject with AIMAH in whom the cortisol secretory pattern and insulin resistance improved concomitantly with the removal of the predominantly enlarged gland. Unilateral adrenalectomy might be an alternative therapy to improve glucose and lipid metabolism in subjects with AIMAH.
